We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has granted priority review to Millennium Pharmaceuticals' supplemental new drug application for Velcade for the treatment of relapsed mantle cell lymphoma, an aggressive, incurable subtype of non-Hodgkin's lymphoma (NHL) for which there is no current standard of care.
Advanced Viral Research has announced that an animal study of the topical application of AVR 118 has shown that the drug accelerates the rate at which wounds heal.
Evotec has announced the successful completion of a Phase I trial of EVT 101, an NR2B subtype-specific NMDA receptor antagonist, for the treatment of Alzheimer's disease and/or neuropathic pain.
Threshold Pharmaceuticals announced it has completed enrollment in a Phase III trial evaluating glufosfamide for the potential second-line treatment of pancreatic cancer, along with a Phase II trial evaluating glufosfamide in combination with gemcitabine for the potential first-line treatment of pancreatic cancer.